NASDAQ:DXR Daxor (DXR) Stock Price, News & Analysis $9.08 -0.17 (-1.87%) Closing price 10/23/2026 03:59 PM EasternExtended Trading$9.21 +0.13 (+1.48%) As of 07:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and TrendsOwnershipSEC Filings About Daxor Stock (NASDAQ:DXR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Daxor alerts:Sign Up Key Stats Today's Range$9.24▼$9.6850-Day Range$9.08▼$11.7252-Week Range$8.56▼$14.76Volume21,054 shsAverage Volume13,939 shsMarket Capitalization$53.01 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingModerate Buy Company Overview Daxor Corporation (NASDAQ: DXR) is a medical device and biotechnology company focused on blood-volume measurement and related diagnostic applications. Its primary product is the BVA-100 Blood Volume Analyzer, a system designed to measure a patient’s total blood volume, plasma volume, red blood cell volume and hematocrit. The BVA-100 uses a blood sample and an iodine-131-labeled albumin tracer to provide quantitative blood-volume measurements. The technology is intended to support clinical assessment and management in areas including heart failure, critical care, kidney disease, blood disorders and perioperative care, where accurate information about a patient’s fluid and blood-volume status can assist treatment decisions. Daxor markets its technology primarily to hospitals and other healthcare providers and also supports clinical research involving blood-volume measurement. The company is headquartered in New York and has been publicly traded under the symbol DXR for several decades. Michael Feldschuh has served as the company’s chief executive officer.AI Generated. May Contain Errors. Read More Receive DXR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Daxor and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DXR Stock News HeadlinesDaxor Accelerates Commercial Expansion of Next-Gen Blood Volume Diagnostic Platform at MedAxiom CV Transforum Fall '26October 15, 2026 | globenewswire.comDaxor Announces Strong Commercial Interest and New Clinical Data at HFSA 2026October 14, 2026 | globenewswire.comFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.October 26 at 1:00 AM | Weiss Ratings (Ad)Daxor to Showcase Blood Volume Analysis Platform at ASN Kidney Week 2026October 13, 2026 | globenewswire.comDaxor to Showcase Next-Gen Blood Volume Analyzer and New Clinical Data at HFSA 2026October 1, 2026 | globenewswire.comDaxor consensus price target decreased by 13.04% to $20.40September 15, 2026 | msn.comDaxor Corporation to Participate in Lake Street’s Tenth Annual BIG10 Conference in New York CitySeptember 8, 2026 | quiverquant.comQDaxor Corporation to Participate in the 10th Annual Lake Street Best Ideas Growth ConferenceSeptember 8, 2026 | globenewswire.comSee More Headlines DXR Stock Analysis - Frequently Asked Questions How have DXR shares performed this year? Daxor's stock was trading at $14.75 on January 1st, 2026. Since then, DXR stock has decreased by 38.5% and is now trading at $9.0770. How do I buy shares of Daxor? Shares of DXR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Daxor own? Based on aggregate information from My MarketBeat watchlists, some other companies that Daxor investors own include Micron Technology (MU), BioLineRx (BLRX), Amicus Therapeutics (FOLD), 3D Systems (DDD), D.R. Horton (DHI), FTI Consulting (FCN) and Petroleo Brasileiro S.A.- Petrobras (PBR). Company Calendar Today10/26/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (6m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 DXR's financial health is in the Red zone, according to TradeSmith. DXR has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:DXR Previous SymbolNYSEAMERICAN:DXR CIK27367 Webwww.daxor.com Phone212-244-0555Fax212-244-0806Employees37Year Founded1970Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares5,840,000Free Float2,831,000Market Cap$53.01 million OptionableNot Optionable Beta0.35 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:DXR) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our Partners“The crisis that’s emerging now is just the tip of the iceberg,” says Dr. Martin D. Weiss, who has made shocking and accurate predictions for 55 yearsDr. Martin D. Weiss, who predicted the Dot-Com collapse and the failures of Fannie Mae, Bear Stearns, and Lehm...Weiss Ratings | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredElon says the ‘S’ wordElon Musk and Sam Altman have sued each other and feuded for years. Yet within days of one another, both men d...Paradigm Press | SponsoredThe chip inside every TeslaEvery Tesla built since 2012 pays this small, overlooked supplier a fee for its technology. So does every Star...Behind the Markets | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | Sponsored80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredFDA clears next-gen therapy with 10 to 40 times greater potencyTime-lapse footage from a recent clinical study shows Natural Killer cells attacking and eliminating cancer ce...Market Tactic | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Daxor Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Daxor With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
